Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s ExosomesTORONTO and HAIFA, Israel, Dec. 12, 2025 ...
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting its ...
Data indicate that the AutoCell platform could pave the way for CGTs for the first time as first-line therapies.
The first GMP cell therapy product ever manufactured for clinical use on the Cell Shuttle™ and released using Cell Q™, is expected to be infused into patients within Cabaletta’s RESET™ clinical trial ...
ASPIRO is the first multi-patient, multi-center clinical trial of an autologous cell therapy for Parkinson's disease. It is evaluating safety, tolerability, and preliminary efficacy of ANPD001 in ...
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome ...
The success of the mRNA vaccines for COVID-19 led to explosive growth in lipid nanoparticle (LNP)-mediated drug delivery for RNA vaccines and therapeutics. As these projects scale into clinical trials ...
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced ...
VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback